Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Feb;141(2 Suppl):e120S-e151S.
doi: 10.1378/chest.11-2294.

New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

Jeffrey I Weitz  1 , John W Eikelboom  2 , Meyer Michel Samama  3
Affiliations
Review

New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

Jeffrey I Weitz et al. Chest. 2012 Feb.

Abstract

This article focuses on new antithrombotic drugs that are in or are entering phase 3 clinical testing. Development of these new agents was prompted by the limitations of existing antiplatelet, anticoagulant, or fibrinolytic drugs. Addressing these unmet needs, this article (1) outlines the rationale for development of new antithrombotic agents; (2) describes the new antiplatelet, anticoagulant, and fibrinolytic drugs; and (3) provides clinical perspectives on the opportunities and challenges faced by these novel agents.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
New antiplatelet drugs. PAR = protease-activated receptor.
Figure 2.
Figure 2.
Sites of action of new anticoagulants in more advanced stages of development. NAPc2 = nematode anticoagulant peptide c2.
Figure 3.
Figure 3.
Classification of new anticoagulants. Indirect anticoagulants act in an AT-dependent fashion or exert their effect via the protein C pathway. Direct anticoagulants do not require a plasma cofactor. Instead, these agents directly target a specific coagulation enzyme. AT = antithrombin. See Figure 2 legend for expansion of other abbreviation.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Freiman D. The structure of thrombi. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, editors. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 2nd ed. Philadelphia, PA: JB Lippincott; 1987. pp. 1123–1135.
    1. Baigent C, Blackwell L, Collins R, et al. Antithrombotic Trialists’ (ATT) Collaboration Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849–1860. - PMC - PubMed
    1. Berger JS, Krantz MJ, Kittelson JM, Hiatt WR. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA. 2009;301(18):1909–1919. - PubMed
    1. Food and Drug Administration Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use; final rule for professional labeling of aspirin, buffered aspirin, and aspirin in combination with antacid drug products. Fed Regist. 1998;63(205):56802–56809. - PubMed
    1. CAPRIE Steering Committee A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) Lancet. 1996;348(9038):1329–1339. - PubMed

MeSH terms